Figure 5 : Quality difference in the antibody response after vaccination and comparison of Pfs25-IMX313 immunogenicity between different vaccination regimes and adjuvants.

From: Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology

Figure 5

Antibody avidity was assessed in day 70 and day 62 serum from mice immunized with viral-vectors (Fig. 2B) and 2.5 μg protein-in-adjuvant vaccines respectively (Fig. 2C). Avidity of serum IgG responses was assessed by NaSCN-displacement ELISA and is reported as the molar concentration of NaSCN required to reduce the OD405 to 50% of that without NaSCN. The isotype profiles (IgG1 and IgG2a) of serum antibody responses were also assessed by ELISA for the same time-points for the viral-vector immunized mice (B) and the protein-in-adjuvant immunized mice (C) (n.d., not detected). BALB/c mice (n = 5 per group) received Pfs25-IMX313 vaccines via the i.m. route in different combination of regimes. A–M and A–P prime-boost regime were 8 weeks apart and P–P was 4 weeks apart. Two weeks after the boost vaccination in each group, serum samples were collected and the total IgG response was measured using a Pfs25 standardized ELISA (D). BALB/c mice (n = 6 per group) received prime-boost vaccinations (2 immunisations, 3 weeks apart) of Pfs25-IMX313 protein-nanoparticle formulated in Alhydrogel, LMQ or MF59. Three weeks after each vaccination, serum samples were collected and the total IgG response was measured using Pfs25 standardized ELISA (E). Mean with SEM are depicted and individual data are shown for all figures. For A, B and C, Mann-Whitney test was performed **p < 0.01. For D and E, Kruskal-Wallis test followed by Dunn’s multiple comparison post-test was performed *p < 0.05, **p < 0.01, ***p < 0.001.